另一篇关于三阴性乳腺癌的综述。我们是否正朝着走出迷宫的正确方向前进？
Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
作者信息
Chiorean Roxana, Braicu Cornelia, Berindan-Neagoe Ioana
机构信息
Clinical University Hospital of Dermatovenereology, Cluj-Napoca, Romania; Department of Dermatology, University of Freiburg, Freiburg, Germany; Department of Functional Genomics and Experimental Pathology, The Oncological Institute - Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania.
出版信息
Breast. 2013 Dec;22(6):1026-33. doi: 10.1016/j.breast.2013.08.007. Epub 2013 Sep 21.
Triple negative breast cancer is a heterogeneous group of tumors, lacking the expression of estrogen, progesterone and HER-2 receptors. As frequency, it accounts about 15-20% of all breast cancers. Although in the last years there was a "boom" in publishing over this issue, multiple molecular classifications being elaborated, "the triple negative breast cancer odyssey " is still far away from ending, as the complicated molecular pathways of pathogenesis and drug resistance mechanisms remain yet insufficiently explored. The aim of this review is presentation of molecular signatures that could predict outcome and drug resistance in triple negative breast cancer.
三阴性乳腺癌是一组异质性肿瘤，缺乏雌激素、孕激素和HER-2受体的表达。其发病率约占所有乳腺癌的15%-20%。尽管近年来关于这个问题的研究如“井喷”般涌现，多种分子分类方法也在不断完善，但由于其发病机制和耐药机制的复杂分子途径仍未得到充分探索，“三阴性乳腺癌之旅”仍远未结束。本综述的目的是介绍能够预测三阴性乳腺癌预后和耐药性的分子特征。
Zotero 插件